Coping Strategies in Male Patients under Treatment for Substance Use Disorders and/or Severe Mental Illness: Influence in Clinical Course at One-Year Follow-Up

Marquez-Arrico, Julia E.; Río-Martínez, Laura; Navarro, José Francisco; Prat, Gemma; Forero, Diego A.; Adán, Ana

doi:10.3390/jcm8111972

Cited by 23 publications

(25 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consistent with previous findings, we did not find any differences between groups in the age of SUD onset between groups (30). The SUD + MDD patients showed higher rates of medical disorder comorbidity (30,37,59) and more suicide attempts (26,28,30,32,37,59,60). In the current research, the SUD + MDD patients reported more personal psychiatric history than the SUD ones (39,61,62), which is in line with a recent study on SUD + MDD patients with lower mental health component compared with the SUD ones (30).…”

Section: Discussionsupporting

confidence: 91%

Circadian Functioning and Quality of Life in Substance Use Disorder Patients With and Without Comorbid Major Depressive Disorder

et al. 2021

Self Cite

View full text Add to dashboard Cite

Aim: Although a relationship between circadian disruption and development of several psychiatric disorders, such as major depressive disorder (MDD) and substance use disorder (SUD), has been observed, knowledge on this area is scarce yet. Therefore, this study aims to analyze the circadian functioning and quality of life (QOL) in SUD patients with and without comorbid MDD, two highly prevalent clinical entities with difficult therapeutic management.Methods: One hundred sixty-three male patients under treatment, 81 with SUD and 82 with SUD comorbid major depressive disorder (SUD + MDD), were evaluated. For the circadian functioning assessment, we calculated Social Jet Lag (SJL) and used the reduced Morningness–Eveningness Questionnaire (rMEQ) and the Pittsburgh Sleep Quality Index (PSQI). QOL was measured using the shortened version of the World Health Organization's Quality of Life Questionnaire (WHOQOL-BREF). We collected sociodemographic and clinical variables to evaluate their possible influence on the circadian functioning. Intergroup differences among the variables were examined by different analyses of covariance (ANCOVA and MANCOVA). The possible relationships of quantitative clinical variables with rMEQ, PSQI, and WHOQOL-BREF were explored using bivariate correlation analysis.Results: Lower SJL appears in the SUD + MDD group compared with SUD. The intermediate-type was more prevalent in the SUD group, while a higher percentage of morning-type patients was found in the SUD + MDD. Sleep quality (including latency and daytime dysfunction) was worse for SUD + MDD patients than for SUD even after controlling age and age of SUD onset variables. Last, QOL was poorer in patients with SUD + MDD and, for them, psychological health had a negative relationship with SJL and severity of depression.Conclusions: Our data support and extend previous findings indicating that SUD + MDD is associated with worse clinical characteristics, more sleep problems, and poorer QOL than SUD patients. These results underline the importance of a precise assessment of these measurements in future studies conducted in SUD patients with/without MDD comorbidity that could be considered from a therapeutic point of view.

show abstract

Section: Discussionsupporting

confidence: 91%

Circadian Functioning and Quality of Life in Substance Use Disorder Patients With and Without Comorbid Major Depressive Disorder

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Relapses at 3 months were related to two different quality of life dimensions depending on whether the patient was asymptomatic SUD + MDD or a patient with SUD. Thus, in patients with SUD, worse physical function (limitations in daily physical activities) was associated with a greater probability of having relapses throughout the year of follow-up (3, 6, and 12 months); these data are in agreement with published studies that associate the use of maladaptive coping strategies with a higher probability of relapse in patients with dual disorders [ 6 , 51 ]. Future studies should deepen this relationship and investigate whether the presence of physical problems in SUD reduces the patient’s motivation to maintain abstinence or whether consumption works as a strategy to cope with these daily limitations.…”

Section: Discussionsupporting

confidence: 89%

“…Both from the field of research and from clinical practice, different indicators of success of the treatment or recovery of the patient are currently being investigated, beyond the simple reduction of psychiatric symptoms and withdrawal from substance use [ 4 , 5 ]. There are different published studies that explain the relevance of certain variables that function as indicators of the patient’s prognosis [ 6 , 7 , 8 ], among which is quality of life [ 8 , 9 ]. Undoubtedly, having indicators at the start of treatment that report a poor clinical evolution can be key for adjusting the intervention to the specific needs of each patient [ 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Health-Related Quality of Life in Male Patients under Treatment for Substance Use Disorders with and without Major Depressive Disorder: Influence in Clinical Course at One-Year Follow-Up

Marquez-Arrico

Navarro

Adán

2020

JCM

Self Cite

View full text Add to dashboard Cite

Health-related quality of life (HRQoL) assessment has interest as an indicator of degree of affectation and prognosis in mental disorders. HRQoL is impaired in both Substance Use Disorder (SUD) and Major Depressive Disorder (MDD), two conditions highly prevalent, although less studied when both are coexisting (SUD + MDD). Hence, we decided to explore HRQoL with the SF-36 survey in a sample of 123 SUD and 114 SUD + MDD patients (51 symptomatic and 63 asymptomatic of depressive symptoms) under treatment. We performed analyses to examine HRQoL among groups, and its predictive value at 3-, 6- and 12-month follow-ups through regression models. Patients with SUD + MDD had worse HRQoL than SUD patients and population norms. For Mental Health, Vitality, and General Health dimensions, lower scores were observed for SUD + MDD regardless the presence/absence of depressive symptoms. For Physical Functioning and Health Change, depressive symptomatology and not the comorbidity of SUD + MDD diagnoses explained HRQoL limitations. At 3-, 6- and 12-month follow-ups we observed two predictors of relapses, General Health for asymptomatic SUD + MDD, and Physical Functioning for SUD. Improving HRQoL in SUD + MDD may be targeted during patient’s treatment; future studies should explore the influence of HRQoL on patient’s prognosis taking into account the presence/absence of depressive symptomatology.

show abstract

“…Accessible mental health services for all patients, with the capacity to promote the rapid reintegration of those who miss appointments also contributes to a better outcome. In addition, simplified therapeutic regimens, considering the introduction of long-acting injectable antipsychotic, contribute to treatment compliance [31,32]. Since the side effects of antipsychotics are sometimes responsible for non-adherence to the treatment, the clinician must monitor its appearance and not devalue their burden on the patient.…”

Section: Discussionmentioning

confidence: 99%

Schizophrenia and substance use disorder: a retrospective study of a dual diagnosis patients cohort

Ventura¹,

Jesús²,

Mendes³

et al. 2021

Psychiatria

View full text Add to dashboard Cite

Introduction: Approximately 47% of patients with Schizophrenia have criteria for a dual diagnosis. The consumption of illicit substances, particularly cannabis, is quite prevalent in these patients, being associated with an increase in mortality and morbidity and worse social outcomes. This study aims to understand the relationship between Schizophrenia and substance use disorders (SUD). Material and methods: A retrospective study was designed, including patients diagnosed with schizophrenia admitted to the Psychiatric Ward between January 2017 and June 2019. Results: 205 patients were included, 49 women (23.9%) and 156 men (76.1%). Of these, 29.1% consumed psychoactive substances at the first hospitalization, mainly cannabis (24.1%), with higher prevalence in men.The average age at the first admission was significantly lower for substance users than for non-users. The presence of consumption in the first hospitalization, the number of hospitalizations and treatment adherence were associated with the maintenance of consumption after the first hospitalization. The presence of consumption at the first hospitalization is a significant predictor of its maintenance. Patients who do not adhere to treatment were more likely to maintain consumption. The number of future hospitalizations was associated with early age at the first hospitalization, non-compliance to treatment and maintenance of consumption after the first hospitalization. Conclusions: We verify that the consumption of psychoactive substances is associated with the early age at the first hospitalization, whit the reduced compliance to treatment and the increased number of hospitalizations. Comorbid substance use disorders should be treated as early as possible to minimize the long-term effects of substance use on patients with schizophrenia in Dual Diagnosis programs.

show abstract

Coping Strategies in Male Patients under Treatment for Substance Use Disorders and/or Severe Mental Illness: Influence in Clinical Course at One-Year Follow-Up

Cited by 23 publications

References 51 publications

Circadian Functioning and Quality of Life in Substance Use Disorder Patients With and Without Comorbid Major Depressive Disorder

Circadian Functioning and Quality of Life in Substance Use Disorder Patients With and Without Comorbid Major Depressive Disorder

Health-Related Quality of Life in Male Patients under Treatment for Substance Use Disorders with and without Major Depressive Disorder: Influence in Clinical Course at One-Year Follow-Up

Schizophrenia and substance use disorder: a retrospective study of a dual diagnosis patients cohort

Contact Info

Product

Resources

About